Cabergoline Effect on Blood Sugar in Type 2 Diabetics
Primary Purpose
Diabetes Type 2
Status
Unknown status
Phase
Not Applicable
Locations
Study Type
Interventional
Intervention
Cabergoline
Sponsored by
About this trial
This is an interventional treatment trial for Diabetes Type 2 focused on measuring diabetes mellitus, FBS, HbA1C, Cabergoline
Eligibility Criteria
Inclusion Criteria:
- Type 2 diabetes
- HbA1C>7
Exclusion Criteria:
- HbA1C>10
- Psychiatric disorders
Sites / Locations
Outcomes
Primary Outcome Measures
FBS (fasting blood sugar)
Secondary Outcome Measures
HbA1C
Full Information
NCT ID
NCT01459601
First Posted
October 24, 2011
Last Updated
October 24, 2011
Sponsor
Mashhad University of Medical Sciences
1. Study Identification
Unique Protocol Identification Number
NCT01459601
Brief Title
Cabergoline Effect on Blood Sugar in Type 2 Diabetics
Official Title
Cabergoline Effects on Blood Sugar Control in Type 2 Diabetics
Study Type
Interventional
2. Study Status
Record Verification Date
October 2011
Overall Recruitment Status
Unknown status
Study Start Date
January 2012 (undefined)
Primary Completion Date
February 2012 (Anticipated)
Study Completion Date
February 2012 (Anticipated)
3. Sponsor/Collaborators
Responsible Party, by Official Title
Principal Investigator
Name of the Sponsor
Mashhad University of Medical Sciences
4. Oversight
Data Monitoring Committee
No
5. Study Description
Brief Summary
Diabetic patients with poorly control blood sugar are prescribed cabergoline for 1 months and their blood glucose is evaluated.
6. Conditions and Keywords
Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Diabetes Type 2
Keywords
diabetes mellitus, FBS, HbA1C, Cabergoline
7. Study Design
Primary Purpose
Treatment
Study Phase
Not Applicable
Interventional Study Model
Single Group Assignment
Masking
Participant
Allocation
Randomized
Enrollment
10 (Anticipated)
8. Arms, Groups, and Interventions
Intervention Type
Drug
Intervention Name(s)
Cabergoline
Other Intervention Name(s)
Dastinex
Intervention Description
0,5mg per week
Primary Outcome Measure Information:
Title
FBS (fasting blood sugar)
Time Frame
30days
Secondary Outcome Measure Information:
Title
HbA1C
Time Frame
30days
10. Eligibility
Sex
All
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria:
Type 2 diabetes
HbA1C>7
Exclusion Criteria:
HbA1C>10
Psychiatric disorders
12. IPD Sharing Statement
Learn more about this trial
Cabergoline Effect on Blood Sugar in Type 2 Diabetics
We'll reach out to this number within 24 hrs